Rheumatoid Arthritis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

According to the latest market report by Fairfield Market Research, the global revenue from the rheumatoid arthritis market is projected to grow at a compound annual growth rate (CAGR) of 5.4%, reaching a valuation of about USD $1104.3 million by the end of 2031 from US$764.2 million in 2024. The market is expected to see substantial growth over the forecast period, contributing significantly to the global autoimmune disease diagnostics market.

Rising Demand for Advanced Diagnostic Solutions

Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling, warmth, and pain due to inflammation of the connective tissue, joints, muscles, tendons, and fibrous tissue. The disease primarily affects the hands, wrists, and feet and is more prevalent in women than men. Early diagnosis and treatment are crucial as RA is incurable. The development of rapid diagnostic test solutions with high specificity and sensitivity is essential to reduce the time and effort required for sample testing.

The global market for rheumatoid arthritis diagnostics and treatments is expected to witness significant growth due to the increasing prevalence of the disease and the rising demand for advanced diagnostic solutions. According to the World Health Organization (WHO), rheumatoid arthritis affects up to 14 million people globally. A study published in Frontiers in Medicine in 2022 highlighted that RA is prevalent among 5% of the population suffering from chronic inflammatory arthritis.

Government Initiatives and Funding Boost Market Growth

Government initiatives and funding play a crucial role in the growth of the rheumatoid arthritis market. Increasing spending by government bodies to develop novel and cost-effective drugs for RA surveillance and treatment are among the key factors driving market growth. Governments are investing in research and development activities to reduce the burden of RA surveillance and treatment.

In 2020, the Centers for Disease Control and Prevention (CDC) provided data on statistics of arthritic patients and arthritis affecting factors on quality of life. The CDC's Arthritis Program, Chronic Disease Self-Management Program, and Physical Activity Programs are raising awareness and diagnosis of RA. These initiatives are expected to promote the growth of RA diagnosis over the forecast period.

Market Projections: USD 764.2 Million in 2024 and USD 1104.3 Million by 2031

The rheumatoid arthritis market is projected to reach USD 764.2 million by 2024 and USD 1104.3 million by 2031, growing at a CAGR of 5.4%. The commercialization of rapid diagnostic test kits with high specificity and sensitivity is expected to increase the demand for RA diagnostic test kits and treatment efficacy monitoring test kits.

Challenges: Limited Specificity and Sensitivity of Test Kits

Despite the positive growth outlook, the market faces challenges related to the limited specificity and sensitivity of rheumatoid arthritis test kits. Conventional test methods, such as erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF) tests, have limited specificity and sensitivity, leading to false positive outcomes. Innovative diagnostic test kits, such as antinuclear antibody (ANA) tests and anti-cyclic citrullinated peptide (anti-CCP) tests, offer higher specificity and sensitivity. However, the high costs of these tests pose a significant challenge to their widespread adoption.

Regional Insights: United States and Germany

The United States held around 14.5% of the global market share in 2022, driven by increasing awareness and government funding. According to the CDC, 58.5 million adults (24%) in the United States have arthritis, with significant costs for medical care and lost wages. The CDC's funding and programs support arthritis self-management education and physical activity, raising awareness about RA detection and treatment.

In Germany, the market held around 6.3% of the global share in 2022, with a focus on the diagnosis and management of juvenile idiopathic arthritis (JIA). The Pediatric Rheumatology Society in Germany (GKJR) and its PRO-KIND Initiative establish harmonized diagnostic and therapeutic strategies for JIA, promoting early prognosis, diagnosis, and appropriate treatment.

Segment Insights: Serology Tests and Diagnostic Laboratories

Serology tests, which held 67.5% of the global market share in 2022, are crucial for the early diagnosis and differentiation of rheumatoid arthritis. These tests detect antibodies produced after exposure to foreign substances or microorganisms, aiding in the diagnosis of autoimmune and immunodeficiency disorders.

Diagnostic laboratories, which held around 41.6% of the global market share in 2022, are preferred for conducting diagnostic tests critical for detecting the disease's initial stages and management. Early detection and treatment with disease-modifying anti-rheumatic drugs (DMARDs) are essential for disease control and prevention of joint injury and disability.

Competitive Analysis

Abbott Diagnostics
Antibodies Incorporated
Beckman Coulter, Inc.
Euro Diagnostica AB
Thermo Fisher Scientific Inc.
Qiagen N.V.
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
Janel Group (Antibodies Inc.)

Key Market Segmentation

Test Type

Serology Tests
- oErythrocyte Sedimentation rheumatoid arthritis (ESR)
- oRheumatoid Factor (RF)
- oAnti-cyclic Citrullinated Peptide (anti-CCP)
- oAntinuclear Antibody (ANA)
- oUric Acid
- oOther Test
Monitoring rheumatoid arthritis Treatment Efficiency Tests
- oSalicylate Level Count
- oMuscle Enzyme Test
- oCreatinine Test

End User

Hospitals
Diagnostic Laboratories
- oPrivate Laboratories
- oPublic Laboratories
Ambulatory Surgical Centers

Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)

1. Executive Summary

1.1. Global Rheumatoid Arthritis Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Rheumatoid Arthritis Market Outlook, 2018 - 2031

3.1. Global Rheumatoid Arthritis Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Symptomatic Treatment
  - 3.1.1.2. Intermediate Corticosteroid Therapies
  - 3.1.1.3. Stem Cell Therapy
  - 3.1.1.4. Disease Modifying Anti-Rheumatic Drug (DMARD)
    - 3.1.1.4.1. Conventional DMARDs
    - 3.1.1.4.2. Biologic DMARDs
3.2. Global Rheumatoid Arthritis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Hospital Pharmacy
  - 3.2.1.2. Retail Pharmacy
  - 3.2.1.3. Drug Stores
3.3. Global Rheumatoid Arthritis Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Rheumatoid Arthritis Market Outlook, 2018 - 2031

4.1. North America Rheumatoid Arthritis Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Symptomatic Treatment
  - 4.1.1.2. Intermediate Corticosteroid Therapies
  - 4.1.1.3. Stem Cell Therapy
  - 4.1.1.4. Disease Modifying Anti-Rheumatic Drug (DMARD)
    - 4.1.1.4.1. Conventional DMARDs
    - 4.1.1.4.2. Biologic DMARDs
4.2. North America Rheumatoid Arthritis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospital Pharmacy
  - 4.2.1.2. Retail Pharmacy
  - 4.2.1.3. Drug Stores
- 4.2.2. Market Attractiveness Analysis
4.3. North America Rheumatoid Arthritis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.2. Market Attractiveness Analysis

5. Europe Rheumatoid Arthritis Market Outlook, 2018 - 2031

5.1. Europe Rheumatoid Arthritis Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Symptomatic Treatment
  - 5.1.1.2. Intermediate Corticosteroid Therapies
  - 5.1.1.3. Stem Cell Therapy
  - 5.1.1.4. Disease Modifying Anti-Rheumatic Drug (DMARD)
    - 5.1.1.4.1. Conventional DMARDs
    - 5.1.1.4.2. Biologic DMARDs
5.2. Europe Rheumatoid Arthritis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospital Pharmacy
  - 5.2.1.2. Retail Pharmacy
  - 5.2.1.3. Drug Stores
- 5.2.2. Market Attractiveness Analysis
5.3. Europe Rheumatoid Arthritis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.2. Market Attractiveness Analysis

6. Asia Pacific Rheumatoid Arthritis Market Outlook, 2018 - 2031

6.1. Asia Pacific Rheumatoid Arthritis Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Symptomatic Treatment
  - 6.1.1.2. Intermediate Corticosteroid Therapies
  - 6.1.1.3. Stem Cell Therapy
  - 6.1.1.4. Disease Modifying Anti-Rheumatic Drug (DMARD)
    - 6.1.1.4.1. Conventional DMARDs
    - 6.1.1.4.2. Biologic DMARDs
6.2. Asia Pacific Rheumatoid Arthritis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospital Pharmacy
  - 6.2.1.2. Retail Pharmacy
  - 6.2.1.3. Drug Stores
- 6.2.2. Market Attractiveness Analysis
6.3. Asia Pacific Rheumatoid Arthritis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.2. Market Attractiveness Analysis

7. Latin America Rheumatoid Arthritis Market Outlook, 2018 - 2031

7.1. Latin America Rheumatoid Arthritis Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Symptomatic Treatment
  - 7.1.1.2. Intermediate Corticosteroid Therapies
  - 7.1.1.3. Stem Cell Therapy
  - 7.1.1.4. Disease Modifying Anti-Rheumatic Drug (DMARD)
    - 7.1.1.4.1. Conventional DMARDs
    - 7.1.1.4.2. Biologic DMARDs
7.2. Latin America Rheumatoid Arthritis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Hospital Pharmacy
  - 7.2.1.2. Retail Pharmacy
  - 7.2.1.3. Drug Stores
- 7.2.2. Market Attractiveness Analysis
7.3. Latin America Rheumatoid Arthritis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.2. Market Attractiveness Analysis

8. Middle East & Africa Rheumatoid Arthritis Market Outlook, 2018 - 2031

8.1. Middle East & Africa Rheumatoid Arthritis Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Symptomatic Treatment
  - 8.1.1.2. Intermediate Corticosteroid Therapies
  - 8.1.1.3. Stem Cell Therapy
  - 8.1.1.4. Disease Modifying Anti-Rheumatic Drug (DMARD)
    - 8.1.1.4.1. Conventional DMARDs
    - 8.1.1.4.2. Biologic DMARDs
8.2. Middle East & Africa Rheumatoid Arthritis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospital Pharmacy
  - 8.2.1.2. Retail Pharmacy
  - 8.2.1.3. Drug Stores
8.3. Middle East & Africa Rheumatoid Arthritis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Rheumatoid Arthritis Market by Therapy, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Rheumatoid Arthritis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.2. Market Attractiveness Analysis

9. Competitive Landscape

9.1. Manufacturer vs by Distribution Channel Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Sanofi S.A.
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Pfizer Inc.
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Johnson & Johnson
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. AbbVie Inc.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. AbbVie Inc.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Eli Lilly & Company
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Amgen Inc.
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Bristol-Myers Squibb Company
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. F. Hoffman-La Roche AG
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Cipla, Inc.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Sun Pharmaceutical Industries Ltd.
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations